Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Soares, Esmeralda A ^a,b   Santos, André F ^a   Gonzalez, Luis M ^a   Lalonde, Matthew S ^b   Tebit, Denis M ^b   Tanuri, Amilcar ^a   Arts, Eric J ^b   Soares, Marcelo A ^a,c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Antiretroviral; Drug resistance; Viral fitness

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; OLIGONUCLEOTIDE; PROTEINASE; RITONAVIR; SAQUINAVIR; SERINE; THREONINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIZATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; VIRUS CULTURE; VIRUS REPLICATION; WILD TYPE; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGICAL EXAMINATION; MISSENSE MUTATION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV-1; HUMANS; INDINAVIR; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; RITONAVIR;

EID: 73949099485     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp315     Document Type: Article

References (37)

1. Ridky T, Leis J. Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem 1995; 270: 29621-3.
2. Garcia-Lerma JG, Heneine W. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing. J Clin Virol 2001; 21: 197-212.
3. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138-45.
4. Brann TW, Dewar RL, Jiang MK et al. Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness. J Virol 2006; 80: 6136-45.
5. Kantor R, Katzenstein DA, Efron B et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2: e112.
6. Paolucci S, Baldanti F, Dossena L et al. Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility. Antivir Res 2006; 69: 181-5.
7. Descamps D, Apetrei C, Collin G et al. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12: 1109-11.
8. Santos AF, Abecasis AB, Vandamme AM et al. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. J Antimicrob Chemother 2009; 63: 593-9.
9. Gonzalez LM, Brindeiro RM, Tarin M et al. In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother 2003; 47: 2817-22.
10. Fonjungo PN, Mpoudi EN, Torimiro JN et al. Human immunodeficiency virus type 1 group M protease in Cameroon: genetic diversity and protease inhibitor mutational features. J Clin Microbiol 2002; 40: 837-45.
11. Vicente AC, Agwale SM, Otsuki K et al. Genetic variability of HIV-1 protease from Nigeria and correlation with protease inhibitors drug resistance. Virus Genes 2001; 22: 181-6.
12. Soares EA, Martinez AM, Souza TM et al. HIV-1 subtype C dissemination in southern Brazil. AIDS 2005; 19 Suppl 4: S81-6.
13. Soares EA, Santos RP, Pellegrini JA et al. Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J Acquir Immune Defic Syndr 2003; 34: 520-6.
14. Deforche K, Silander T, Camacho R et al. Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. Bioinformatics 2006; 22: 2975-9.
15. Gonzalez LM, Santos AF, Abecasis AB et al. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. J Antimicrob Chemother 2008; 61: 1201-4.
16. Adachi A, Gendelman HE, Koenig S et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59: 284-91.
17. Gonzalez LM, Aguiar RS, Afonso A et al. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. J Gen Virol 2006; 87: 1303-9.
18. Maschera B, Furfine E, Blair ED. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 1995; 69: 5431-6.
19. Hertogs K, de Bethune MP, Miller V et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-76.
20. Lalonde MS, Troyer RM, Syed AR et al. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007; 45: 2604-15.
21. Velazquez-Campoy A, Todd MJ, Vega S et al. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci USA 2001; 98: 6062-7.
22. Arien KK, Abraha A, Quinones-Mateu ME et al. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79: 8979-90.
23. Ball SC, Abraha A, Collins KR et al. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003; 77: 1021-38.
24. Marozsan AJ, Moore DM, Lobritz MA et al. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 2005; 79: 7121-34.
25. Nijhuis M, van Maarseveen NM, Boucher CA. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol 2009: 299-320.
26. van Maarseveen NM, de Jong D, Boucher CA et al. An increase in viral replicative capacity drives the evolution of protease inhibitorresistant human immunodeficiency virus type 1 in the absence of drugs. J Acquir Immune Defic Syndr 2006; 42: 162-8.
27. Winters B, Montaner J, Harrigan PR et al. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr 2008; 48: 26-34.
28. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-9.
29. Kuritzkes DR, Quinn JB, Benoit SL et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10: 975-81.
30. de Mendoza C, Valer L, Bacheler L et al. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS 2006; 20: 1071-4.
31. Martinez-Picado J, Savara AV, Shi L et al. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000; 275: 318-22.
32. Dam E, Quercia R, Glass B et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 2009; 5: e1000345.
33. Parry CM, Kohli A, Boinett CJ et al. Gag determinants of fitness and drug susceptibility in protease inhibitor resistant HIV-1. J Virol 2009; doi:10.1128/JVI.02356-08.
34. Andreoni M. Viral phenotype and fitness. New Microbiol 2004; 27: 71-6.
35. Rodriguez MA, Ding M, Ratner D et al. High replication fitness and transmission efficiency of HIV-1 subtype C from India: implications for subtype C predominance. Virology 2009; 385: 416-24.
36. Ho SK, Coman RM, Bunger JC et al. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 2008; 378: 272-81.
37. Verlinden Y, Vermeiren H, Lecocq P et al. Assessment of the antivirogramw performance over time including a revised definition of biological test cut-off values. Antivir Ther 2005; 10 Suppl 2: S51.